These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 183788

  • 1. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J, Dreux C, Goussault Y, Dakkak R, Renson FJ.
    Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
    [Abstract] [Full Text] [Related]

  • 2. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.
    Wülfert B, Majoie B, de Ceaurriz A.
    Arzneimittelforschung; 1976; 26(5):906-9. PubMed ID: 183789
    [Abstract] [Full Text] [Related]

  • 3. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J, Schwartzkopff W, Zschiedrich M.
    Verh Dtsch Ges Inn Med; 1976; 83():392-5. PubMed ID: 206057
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
    Grandjean EM, Mordasini R, Paumgartner G.
    Schweiz Med Wochenschr; 1979 Apr 21; 109(16):601-2. PubMed ID: 219470
    [Abstract] [Full Text] [Related]

  • 5. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A, Buzzelli G, D'Alessandro A.
    Clin Ter; 1979 Apr 30; 89(2):127-49. PubMed ID: 226307
    [No Abstract] [Full Text] [Related]

  • 6. Gemfibrozil treatment: a comparison with clofibrate.
    Howard AN, Ghosh P.
    Proc R Soc Med; 1976 Apr 30; 69 Suppl 2(Suppl 2):88-9. PubMed ID: 190609
    [Abstract] [Full Text] [Related]

  • 7. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
    Klemens UH, von Löwis P.
    Dtsch Med Wochenschr; 1973 Jun 15; 98(24):1197-202. PubMed ID: 4350685
    [No Abstract] [Full Text] [Related]

  • 8. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR, Klemens UH, Vollmar LJ, Lang PD.
    Med Klin; 1978 Dec 08; 73(49):1731-7. PubMed ID: 723760
    [Abstract] [Full Text] [Related]

  • 9. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J, Sauvanet JP, Chanu B, Bakir R, Goy-Loeper J, Saya C, Pinaroli F.
    Nouv Presse Med; 1980 Dec 22; 9(49):3747-51. PubMed ID: 7208341
    [Abstract] [Full Text] [Related]

  • 10. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W, Kremer GJ, Müller D.
    MMW Munch Med Wochenschr; 1975 Oct 31; 117(44):1783-6. PubMed ID: 171564
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM, Levy RI.
    Cardiovasc Clin; 1974 Oct 31; 6(2):1-8. PubMed ID: 4374303
    [No Abstract] [Full Text] [Related]

  • 13. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J, Martorell J.
    Clin Ther; 1980 Oct 31; 3(4):234-41. PubMed ID: 7273061
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J, Bang HO.
    Acta Med Scand; 1976 Oct 31; 200(1-2):55-58. PubMed ID: 183462
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Oct 31; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H, Parwaresch MR, Mäder C.
    Med Klin; 1977 Jul 08; 72(27):1183-7. PubMed ID: 196168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.